COMMUNIQUÉS West-GlobeNewswire

Best Testosterone Booster for Men – Why TestoPrime is the Top Choice for Libido, Performance, and Vitality
15/05/2025
Explore how TestoPrime naturally enhances testosterone to improve energy, improve libido, sexual health and support performance, offering a safe and effective alternative to conventional treatments for Erectile [...]
Best SARMs For Sale: Buy Legal SARMs For Bodybuilding & Cutting Cycles - Crazybulk
15/05/2025
Bodybuilding support made simple. Find top SARMs for sale, ideal for cutting or bulking cycles, all with legal, safe alternatives in one guide by Crazybulk New York City, NY, May 15, 2025 (GLOBE NEWSWIRE) -- [...]
Dianabol (Dbol) For Sale 2025: Best Legal Dbol Pills, Cycles & Stacking Guide
15/05/2025
Looking for Dianabol in 2025? Find legal Dbol pills, smart stacking advice, and trusted options for muscle and recovery support backed by Wolfson Brands (UK) Limited New York City, NY, May 15, 2025 (GLOBE NEWSWIRE) -- [...]
Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update
15/05/2025
DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today [...]
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update
15/05/2025
LYTENAVA™ (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025 Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in the United States [...]
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results
15/05/2025
Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral Small Molecule [...]
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
15/05/2025
Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Italy CNTY-308 expected [...]
vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update
15/05/2025
Ongoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D) Topline Phase 3 data for cadisegliatin expected in 2H 2026 HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv [...]
SRx Health Solutions Announces First Quarter 2025 Financial Results
15/05/2025
EPS Improved 90% Year-Over-Year to $(0.37) Adjusted EBITDA 1 Loss Improved 54% Year-Over-Year to $(0.6) Million Adjusted EBITDA Margin 1 Improved (9)% , a 865 Basis Point Expansion Year-Over-Year TAMPA, Fla., May 15, [...]
Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights
15/05/2025
– 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment – – Full data set from RECOVER OLE highlighting clinical [...]
Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
15/05/2025
New Analysis Shows Treatment with Investigational Paltusotine Resulted in Rapid and Durable IGF-1 Control in Surgically Naïve Acromegaly Patients Additional Research Includes Acromegaly Symptom Burden and Standard-of- [...]
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
15/05/2025
Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint stockholders to [...]
Senseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private Placement
15/05/2025
GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose [...]
Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates
15/05/2025
- Duchenne (SGT-003) : Participant dosing ongoing in the Phase 1/2 INSPIRE DUCHENNE trial; Solid on track to discuss accelerated pathways with U.S. FDA later in 2025 - - FA (SGT-212): Dosing of first participant [...]
Range Impact Reports 1Q 2025 Financial Results
15/05/2025
Cleveland, Ohio, May 15, 2025 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTCQB: RNGE) (“Range Impact” or the “Company”), a public impact investing company dedicated to acquiring, reclaiming and repurposing mine sites in [...]
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025
15/05/2025
BASEL, Switzerland and LONDON and NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 29, 2025, to [...]
Milestone Scientific Reports Revenue of $2.2 Million and Provides Business Update for the First Quarter of 2025
15/05/2025
Reports Increased CompuFlo® Adoption Following Assignment of Favorable Medicare Payment Rates; Expands Federal Outreach Following FSS Contract Award ROSELAND, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific [...]
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
15/05/2025
Ibrexafungerp clinical hold lifted by the FDA. SCYNEXIS working to resolve a disagreement with GSK involving the restart of the MARIO study. GSK remains committed to the commercialization of Brexafemme. Hansoh recently [...]
Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update
15/05/2025
Year-over-year product revenue increased 8%, and year-over-year operating expenses decreased 5% as Vivos sets the stage for its Sleep Center of Nevada acquisition and continued advancement of its new marketing and [...]

Pages